Objective: To review the literature on respiratory syncytial virus (RSV) as a cause of nosocomial infections (NI) on neonatal intensive care units (NICUs) and pediatric wards, and the effectiveness of various containment strategies.
Introduction
Respiratory syncytial virus (RSV) infection is a major cause of significant lower respiratory tract disease in young children and nearly all become infected by age 2.
1 RSV was first identified as a human viral pathogen in 1956 2 and RSV nosocomial infection (NI) outbreaks were recognized shortly thereafter. 3, 4 The body of literature throughout each of the past four decades confirms RSV NI is a consistent problem and the most common, and expensive, cause of NI in neonatal intensive care units (NICUs) and pediatric wards. [5] [6] [7] The purpose of this review is to determine the extent and clinical features of RSV NI in pediatric hospital settings, describe the effectiveness of a range of infection control measures and to provide the most current information on the role of palivizumab in the prevention of further spread of RSV in the NICU and pediatric wards.
Methods
A computerized search of the literature using OVID (contents included Medline and Current Contents) was conducted to identify studies that reported on RSV NI rates in hospital settings with emphasis on NICUs and pediatric wards, and infection containment programs instituted to curtail spread of further infection. Search terms included respiratory syncytial virus, nosocomial infection, infection control, neonatal intensive care, palivizumab and outbreaks. Given that RSV was first isolated in 1956 before widespread awareness of hospital infection control programs, this review focuses on RSV NI rates reported since the early 1960s and evaluates whether infection rates have declined as infection control programs matured. Our search was limited to peer-reviewed English language journals.
We identified the following types of reports pertaining to RSV NI and each was included in our review: prospective controlled trials, prospective studies with before/after intervention methodology, retrospective observational studies and anecdotal/case reports. Many of the early reports identified were anecdotal in nature, whereas more recent studies included data on RSV NI rates before and after specified interventions were instituted. Although anecdotal reports are useful in establishing NI rates, the majority of studies profiled included 'before and after' data regardless of whether they were prospective or retrospective in design. Palivizumab was first approved for use in 1998 and since reports on its use for prevention of RSV NI are limited at this time, all were included in the review. Variables that were evaluated for RSV NI included transmission rates, standardized incubation periods, clinical features and infection control measures utilized alone or in combination with other methods.
Results

Transmission rates
The transmission rates for RSV NI noted in the literature vary widely and this variance has remained fairly consistent over the past four decades in spite of adoption of infection control practices. Criteria used for definition of RSV NI vary with respect to incubation period and range from 72 h to 7 days after admission. 7,8,17,20,23 -25,28 The majority of studies that include incubation data define RSV NI as an infection identified 5 or more days after hospital admission and confirmed by assay or culture. Several methods for calculation of RSV NI transmission rates have been reported and include number of NI cases observed divided by total number of contacts on the ward, cross-infection rates and number of NI cases per number of patient-care days. 15, 22, 24, 25, 27 When specified, RSV NI was identified between 12 and 31 days after admission of the index case and prolonged shedding lasting up to 20 days or more was common in general NICU settings. 9, 15, 17, 29 The length of hospital stay for RSV NI patients can be substantially longer than for those who become infected in the community.
23,28
Clinical features
The clinical presentation of RSV infection of those who acquire it in the hospital may be somewhat different from infection acquired in the community, especially in young infants. 14, 18, 30 The diagnosis of RSV may be missed or delayed in NICU settings due to the sporadic nature of outbreaks and the atypical or mild presentation of disease that can mimic other common illnesses. 14, 18, 26, 29, 30 A delay of 9 days in recognition of an outbreak of RSV was noted in a retrospective evaluation of RSV NI following an outbreak in a NICU in which fever was absent in all infants.
14 Bradycardia, an atypical presentation of RSV NI, was the main presenting clinical symptom in the majority of infants in a NICU in Germany during the course of epidemics observed over three consecutive seasons. 31 Although death is usually a rare occurrence, 8, [32] [33] [34] an overall mortality rate of 15% was reported in one study with congenital heart disease (CHD) being the major underlying condition in patients who died. 28 Potential contributing risk factors for development of RSV NI included prematurity, lung disease, heart disease and immunosuppression. 23 
Source
The role of house staff in the transmission of RSV in hospital settings cannot be overstated. [15] [16] [17] [18] [35] [36] [37] In a study of 24 staff that worked on a children's ward, 10 (42%) acquired RSV over a 2-month period. 15 A total of 66 patients were under their careF22 were admitted with RSV and 12 of the remaining 44 patients acquired the virus in the hospital. All infected staff experienced respiratory symptoms of some kind and viral shedding lasted up to 5 days. In a subsequent study, 24 of 43 (56%) hospital staff members acquired RSV on average 18 to 19 days after admission of the first patient with RSV to their ward; 4 became reinfected within weeks of initial infection. 17 Viral shedding was observed for up to 11 days. Of note, despite implementation of infection control procedures the staff RSV NI rate actually increased from earlier observations. The presence of patients who shed RSV for an extended period on pediatric wards served as a source for RSV NI in some studies. 28 
Infection control methods and techniques
Numerous infection control methods have been evaluated, either alone or in combination, regarding their effectiveness for prevention of nosocomial viral infections including RSV in NICUs (Table 1) . Each has met with varying degrees of success and differences in study design have made it difficult to rate the relative effectiveness of each protocol. Most studies were not sufficiently powered to detect significant differences. A set of guidelines for prevention and control of RSV NI have been published by CDC 38 and others, 39 and many hospitals have adopted institution-specific protocols based on prior experiences. Of all methods evaluated, adequate handwashing/hand decontamination, rapid screening of infected patients and cohorting of children and hospital staff appear to offer the greatest barriers to NI. 6,20,22,25,26,40 -45 Placing limits on sibling visits as well as designing NICUs with individual rooms as opposed to pods has also been utilized. In addition, the prophylactic administration of palivizumab has proven to be successful in preventing further spread of RSV in clinical settings when other containment measures failed.
14,33
Handwashing RSV is a labile virus and is rapidly inactivated by alcohol, dishwashing detergents and antibacterial hand soaps. 6, 40 As noted by the CDC, it is recommended that health-care practitioners decontaminate their hands after contact with a patient or after touching respiratory secretions. 38 Soap and water is recommended when hands are visibly dirty or contaminated with proteinaceous material, blood or other body fluids; alcohol-based rubs may be used when hands are not visibly soiled. 38, 39 Thus, handwashing is the simplest of all infection control methods and has long been recognized as a mainstay for prevention and containment of health care-associated NI. 37, 41 Isaacs et al. 19 examined the incidence of RSV NI in children <2 years of age and in those with CHD over a 2-year period following the emphasis of strict handwashing and patient cohorting procedures. After interventions were in place, the overall rate of RSV NI decreased from 4.2% to 0.6 to 1.1%; the incidence of RSV NI in those with CHD decreased from 34.8% to 2.1 to 3.3%. Compliance by nurses and physicians with acceptable hand hygiene practices is far from satisfactory with the majority of health-care practitioners failing to adhere to appropriate handwashing techniques.
42-44
Rapid screening and cohorting of patients on admission Cohorting of infants with RSV at admission or shortly thereafter following results of prospective RSV diagnostic screening has consistently been shown to be an effective method to reduce RSV NI transmission. 10, 20, 22, 25, 26, 45 Karanfil et al. 20 reported on their RSV NI control plan following two seasonal outbreaks in which 16.5% of RSV cases were nosocomially acquired. 20 During the 2 years after rapid screening was instituted, the incidence of RSV NI decreased by more than 50%. The benefits of the program continued to be demonstrated during the first 6 years it was adopted, resulting in approximately 14 cases of RSV prevented yearly and potential savings of more than $84 000 in hospital costs.
Krasinski et al. 22 adopted a program of rapid screening of patients at admission and assignment to either an infected or uninfected cohort following the observation of a preintervention RSV NI rate of 7.17 cases of RSV per 1000 patient days. During the first two seasons that rapid screening was initiated, the NI rate dropped significantly to less than 1 case per 1000 patient days. The investigators concluded prospective rapid screening for RSV and cohorting of patients on admission are effective control methods for reduction of transmission of RSV within the hospital environment.
Gloves and gowns
The use of gloves and gowns for prevention and spread of NI has been assessed as sole components as well as part of broader infection control plans.
7,14,21,23-27 Leclair et al. 24 assessed compliance with the use of gloves and gowns over three seasons for prevention of RSV NI on an infant and toddler ward. More than 50% of nursing staff were noncompliant with isolation precautions during the first half of the study; however, compliance rates increased to 81 and 95% after the second and third assessments, respectively. The incidence of RSV NI was 6.4 cases per 1000 patient days prior to the intervention and decreased to 3.1 cases per 1000 patient days. The adjusted risk of acquiring RSV NI was almost three times greater for children when compliance with infection control precautions was low. The investigators speculated continued reinforcement of the positive impact of the initiative, strong support from the head nurse and increased access to gloves and gowns were responsible for the observed increase in compliance rates.
Some clinicians have noted spread of infection following the use of gowns and gloves and caution that these objects can act as fomites. The individual contributions of gowning and gloving when practiced together were inferior to a more comprehensive program of gowning, gloving and cohort nursing in one study, 25 while gowning actually increased the risk of transmission in another. 23 Cohorting of ward staff and limiting family visits Cohorting of nursing staff to care for isolated patients has not been evaluated as a lone infection control practice and is always employed as part of broader management programs. 7, 17, 25, 28 Family members and other visitors who have respiratory symptoms should not be allowed to come in contact with patients. 17, 40 Some NICUs limit sibling visits to once per week during the RSV season, in an attempt to reduce RSV exposure.
Palivizumab
Palivizumab is currently indicated for prevention of serious lower respiratory tract disease caused by RSV in pediatric patients at high risk of RSV disease. As part of a pivotal registration study in 1287 children with CHD, Feltes et al. 46 noted fewer instances of RSV NI in those assigned to palivizumab compared with those given placebo. The trial, however, was not specifically designed to examine the effectiveness of palivizumab for prevention of RSV NI. Several clinicians have described their experience with palivizumab specifically for prevention and/or treatment of RSV NI in critical care units. 9,14,21,34,36,47 -49 In these reports, palivizumab (single or multiple injections) was used as an additional measure following poor results with standard infection control practices. In some studies, palivizumab was administered to infants who qualified for its use based on American Academy of Pediatrics (AAP) guidelines (for example, degree of prematurity, underlying risk factors), while in others it was administered as a preventive measure to all infants in the hospital unit regardless of gestational age or concomitant disorders. Although none of these evaluations were conducted under controlled conditions, some investigators concluded further study is warranted especially in uninfected infants who are in close proximity to an infant who develops RSV. 50 Abadesso et al. 49 identified two separate outbreaks of RSV NI in their NICU that were not satisfactorily managed despite implementation of standard infection control procedures. Four of five infants were born less than 32 weeks gestation and one died. Palivizumab 15 mg per kg was subsequently administered to all 19 infants in the NICU followed by a second dose 1 month later; no additional RSV positive cases were identified.
Cox and associates observed an outbreak of RSV NI over a 2-month period that affected seven premature infants in a special care baby unit despite implementation of infection control measures. 33 Palivizumab 15 mg per kg was administered to eight infants on the unit, all who were born prematurely and satisfied AAP guidelines for therapy. Although only one dose was administered, all infants remained free of infection.
Halasa et al.
14 identified an outbreak of RSV NI in nine infants, five of whom required intubation, in the NICU. Various control measures were instituted immediately, including cohorting-infected babies, gowns/gloves, handwashing as well as administration of a single dose of palivizumab 15 mg per kg to the 49 exposed uninfected infants. No further cases of NI were noted after day 14 of the outbreak.
Kilani and associates reported on an outbreak of RSV NI in 8 of 20 infants in the NICU. 21 Associated risk factors included prematurity and low birth weight. Routine infection precautions were instituted along with palivizumab and no further outbreaks occurred. The investigators noted they routinely administer palivizumab to all preterm infants in the NICU once an index case of RSV is identified.
Heerens et al. 47 described sporadic cases of RSV NI in the NICU and noted the difficulty in diagnosis due to the lack of specific symptoms in some patients. In addition to routine infection control measures, they selectively administer palivizumab to patients at greatest risk of RSV and recognize the need for further prospective trials in the NICU setting.
Salcedo et al. 48 observed an outbreak of RSV NI in 4 of 52 neonates. In addition to infection control measures, palivizumab was administered to all infants and no further positive cases were reported. Three of the four positive infants were reported to be free of RSV 6 days after palivizumab administration. A similar outbreak that previously occurred in the facility before the availability of palivizumab could not be managed with infection control practices alone. Summary RSV is the leading cause of NI on NICU and other pediatric wards. RSV NI transmission rates reported in the literature have remained fairly constant over the past 40 years in spite of adoption of standard hospital infection containment programs at many institutions. Outbreaks of RSV can usually be successfully managed through various containment strategies although reports to date have not been of sufficient study quality to suggest one method is overwhelmingly better than others. Compliance with rapid diagnosis, adequate handwashing techniques and cohorting of patients appear to be best. If these measures fail in the NICU or other pediatric wards, a number of recent uncontrolled reports suggest a single or multiple dose of palivizumab may halt further spread of RSV especially in patients for whom such therapy is otherwise recommended. However, randomized, prospective trials should be performed before its use can be more widely adopted in this setting.
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